Loading...

Jagsonpal Pharmaceuticals

NSEI:JAGSNPHARM
Snowflake Description

Excellent balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
JAGSNPHARM
NSEI
₹622M
Market Cap
  1. Home
  2. IN
  3. Pharmaceuticals & Biotech
Company description

Jagsonpal Pharmaceuticals Limited develops and manufactures active pharmaceutical ingredients (APIs) and formulations. The last earnings update was 51 days ago. More info.


Add to Portfolio Compare Print
  • Jagsonpal Pharmaceuticals has significant price volatility in the past 3 months.
JAGSNPHARM Share Price and Events
7 Day Returns
-3%
NSEI:JAGSNPHARM
2.8%
IN Pharmaceuticals
1.3%
IN Market
1 Year Returns
1.9%
NSEI:JAGSNPHARM
-9.6%
IN Pharmaceuticals
-1.5%
IN Market
JAGSNPHARM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Jagsonpal Pharmaceuticals (JAGSNPHARM) -3% -11.4% -6.1% 1.9% -37.8% 6.2%
IN Pharmaceuticals 2.8% 2.7% -10.9% -9.6% -24.2% 5.9%
IN Market 1.3% -0.8% -3.7% -1.5% 22.6% 33.9%
1 Year Return vs Industry and Market
  • JAGSNPHARM outperformed the Pharmaceuticals industry which returned -9.6% over the past year.
  • JAGSNPHARM outperformed the Market in India which returned -1.5% over the past year.
Price Volatility
JAGSNPHARM
Industry
5yr Volatility vs Market

Value

 Is Jagsonpal Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Jagsonpal Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is ₹24.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Jagsonpal Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Jagsonpal Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NSEI:JAGSNPHARM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in INR ₹2.75
NSEI:JAGSNPHARM Share Price ** NSEI (2019-07-18) in INR ₹24
India Pharmaceuticals Industry PE Ratio Median Figure of 116 Publicly-Listed Pharmaceuticals Companies 16.86x
India Market PE Ratio Median Figure of 2,835 Publicly-Listed Companies 14.68x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Jagsonpal Pharmaceuticals.

NSEI:JAGSNPHARM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NSEI:JAGSNPHARM Share Price ÷ EPS (both in INR)

= 24 ÷ 2.75

8.73x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Jagsonpal Pharmaceuticals is good value based on earnings compared to the IN Pharmaceuticals industry average.
  • Jagsonpal Pharmaceuticals is good value based on earnings compared to the India market.
Price based on expected Growth
Does Jagsonpal Pharmaceuticals's expected growth come at a high price?
Raw Data
NSEI:JAGSNPHARM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 8.73x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
19.7%per year
India Pharmaceuticals Industry PEG Ratio Median Figure of 31 Publicly-Listed Pharmaceuticals Companies 1.5x
India Market PEG Ratio Median Figure of 537 Publicly-Listed Companies 1.3x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Jagsonpal Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Jagsonpal Pharmaceuticals's assets?
Raw Data
NSEI:JAGSNPHARM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in INR ₹40.04
NSEI:JAGSNPHARM Share Price * NSEI (2019-07-18) in INR ₹24
India Pharmaceuticals Industry PB Ratio Median Figure of 135 Publicly-Listed Pharmaceuticals Companies 1.51x
India Market PB Ratio Median Figure of 3,670 Publicly-Listed Companies 0.95x
NSEI:JAGSNPHARM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NSEI:JAGSNPHARM Share Price ÷ Book Value per Share (both in INR)

= 24 ÷ 40.04

0.6x

* Primary Listing of Jagsonpal Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Jagsonpal Pharmaceuticals is good value based on assets compared to the IN Pharmaceuticals industry average.
X
Value checks
We assess Jagsonpal Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Jagsonpal Pharmaceuticals has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Jagsonpal Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover Jagsonpal Pharmaceuticals, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
19.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Jagsonpal Pharmaceuticals expected to grow at an attractive rate?
  • Jagsonpal Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 7.6%.
Growth vs Market Checks
  • Jagsonpal Pharmaceuticals's earnings growth is expected to exceed the India market average.
  • Unable to compare Jagsonpal Pharmaceuticals's revenue growth to the India market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NSEI:JAGSNPHARM Future Growth Rates Data Sources
Data Point Source Value (per year)
NSEI:JAGSNPHARM Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts 19.7%
India Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 20.1%
India Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 11.1%
India Market Earnings Growth Rate Market Cap Weighted Average 17%
India Market Revenue Growth Rate Market Cap Weighted Average 9.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NSEI:JAGSNPHARM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in INR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NSEI:JAGSNPHARM Past Financials Data
Date (Data in INR Millions) Revenue Cash Flow Net Income *
2019-03-31 1,668 72
2018-12-31 1,611 30
2018-09-30 1,573 -10
2018-06-30 1,421 -66
2018-03-31 1,266 -16 -116
2017-12-31 1,234 -95
2017-09-30 1,193 26
2017-06-30 1,305 70
2017-04-01 1,441 -32 119
2016-12-31 1,534 131
2016-09-30 1,537 35
2016-06-30 1,466 34

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Jagsonpal Pharmaceuticals's earnings are expected to grow by 19.7% yearly, however this is not considered high growth (20% yearly).
  • Unable to determine if Jagsonpal Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NSEI:JAGSNPHARM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Jagsonpal Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NSEI:JAGSNPHARM Past Financials Data
Date (Data in INR Millions) EPS *
2019-03-31 2.75
2018-12-31 1.14
2018-09-30 -0.37
2018-06-30 -2.48
2018-03-31 -4.41
2017-12-31 -3.61
2017-09-30 1.01
2017-06-30 2.69
2017-04-01 4.53
2016-12-31 4.97
2016-09-30 1.33
2016-06-30 1.30

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Jagsonpal Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Jagsonpal Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the India market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the India market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Jagsonpal Pharmaceuticals has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Jagsonpal Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Jagsonpal Pharmaceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Jagsonpal Pharmaceuticals's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
  • Jagsonpal Pharmaceuticals has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Jagsonpal Pharmaceuticals has become profitable in the last year making it difficult to compare the IN Pharmaceuticals industry average.
Earnings and Revenue History
Jagsonpal Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Jagsonpal Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NSEI:JAGSNPHARM Past Revenue, Cash Flow and Net Income Data
Date (Data in INR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 1,668.26 72.16 466.11
2018-12-31 1,611.20 29.72 483.60
2018-09-30 1,572.82 -9.79 460.41
2018-06-30 1,420.64 -66.03 444.43
2018-03-31 1,265.56 -115.51 434.05
2017-12-31 1,234.13 -94.65 425.39
2017-09-30 1,192.73 26.46 417.96
2017-06-30 1,305.25 70.03 393.78
2017-04-01 1,440.65 118.65 424.35
2016-12-31 1,534.32 130.50 435.41
2016-09-30 1,536.60 34.95 430.80
2016-06-30 1,466.10 34.30 407.62
2016-03-31 1,434.88 32.54 397.15
2015-12-31 1,434.16 13.21 563.77
2015-09-30 1,412.34 9.98 546.08
2015-06-30 1,412.26 9.27 314.00
2015-03-31 1,381.51 11.71 334.23
2014-12-31 1,305.84 23.25 568.26
2014-09-30 1,358.56 31.88 585.13
2014-06-30 1,396.85 28.27 467.84
2014-03-31 1,438.51 21.21 604.96
2013-12-31 1,507.03 12.27 609.85
2013-09-30 1,623.23 14.22 616.72
2013-06-30 1,673.16 18.36 373.33
2013-03-31 1,664.64 18.33 615.01
2012-12-31 1,697.93 24.44 662.61
2012-09-30 1,670.69 36.83 661.08

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Jagsonpal Pharmaceuticals has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Jagsonpal Pharmaceuticals used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
  • Jagsonpal Pharmaceuticals's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Jagsonpal Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Jagsonpal Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Jagsonpal Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Jagsonpal Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Jagsonpal Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Jagsonpal Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Jagsonpal Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 25.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Jagsonpal Pharmaceuticals Company Filings, last reported 3 months ago.

NSEI:JAGSNPHARM Past Debt and Equity Data
Date (Data in INR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 1,044.73 37.85 385.35
2018-12-31 1,005.44 60.36 287.28
2018-09-30 1,005.44 60.36 287.28
2018-06-30 980.47 83.01 145.12
2018-03-31 980.47 83.01 145.12
2017-12-31
2017-09-30 1,018.40 0.00 94.17
2017-06-30 1,099.14 79.28 200.60
2017-04-01 1,099.14 79.28 200.60
2016-12-31 995.09 147.33 134.01
2016-09-30 995.09 147.33 134.01
2016-06-30 983.65 384.93 155.33
2016-03-31 983.65 384.93 155.33
2015-12-31 963.30 384.12 144.17
2015-09-30 963.30 384.12 144.17
2015-06-30 954.26 393.11 150.16
2015-03-31 954.26 393.11 150.16
2014-12-31 996.65 359.38 126.51
2014-09-30 996.65 359.38 126.51
2014-06-30 985.89 359.58 126.04
2014-03-31 985.89 359.58 126.04
2013-12-31 983.81 334.87 91.31
2013-09-30 983.81 334.87 91.31
2013-06-30 983.71 334.07 103.43
2013-03-31 983.71 334.07 103.43
2012-12-31 989.45 357.44 96.59
2012-09-30 989.45 357.44 96.59
  • Jagsonpal Pharmaceuticals's level of debt (3.6%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (36.5% vs 3.6% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Interest payments on debt are well covered by earnings (EBIT is 11.2x coverage).
X
Financial health checks
We assess Jagsonpal Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Jagsonpal Pharmaceuticals has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Jagsonpal Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.04%
Current annual income from Jagsonpal Pharmaceuticals dividends.
If you bought ₹2,000 of Jagsonpal Pharmaceuticals shares you are expected to receive ₹21 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Jagsonpal Pharmaceuticals's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.56%).
  • Jagsonpal Pharmaceuticals's dividend is below the markets top 25% of dividend payers in India (2.21%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NSEI:JAGSNPHARM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
India Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 74 Stocks 0.8%
India Market Average Dividend Yield Market Cap Weighted Average of 1446 Stocks 1.4%
India Minimum Threshold Dividend Yield 10th Percentile 0.3%
India Bottom 25% Dividend Yield 25th Percentile 0.6%
India Top 25% Dividend Yield 75th Percentile 2.2%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NSEI:JAGSNPHARM Past Annualized Dividends Data
Date (Data in ₹) Dividend per share (annual) Avg. Yield (%)
2019-05-28 0.250 0.939
2018-08-09 0.100 0.356
2018-06-28 0.100 0.397
2017-10-03 0.100 0.315
2016-05-30 0.100 0.269
2015-09-02 0.100 0.272
2015-05-29 0.100 0.366
2014-09-08 0.500 1.701
2013-10-09 0.500 4.109
2013-05-30 0.500 5.550
2012-06-12 0.500 4.068
2012-05-30 0.500 4.017
2011-08-12 0.500 3.941
2011-05-13 0.500 3.434
2010-08-16 0.500 2.448
2010-08-13 0.500 2.197
2009-10-01 0.250 1.272

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • No dividend growth in 10 years.
Current Payout to shareholders
What portion of Jagsonpal Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Dividends paid are thoroughly covered by earnings (11x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Jagsonpal Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Jagsonpal Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Jagsonpal Pharmaceuticals has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Jagsonpal Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rajpal Kochhar
COMPENSATION ₹0
AGE 64
TENURE AS CEO 11.3 years
CEO Bio

Mr. Rajpal P. Singh Kochhar has been the Managing Director of JAGSONPAL Pharmaceuticals Ltd. since April 1, 2008 and serves as its Chairman of the Board. Mr. Kochhar has 28 years of experience. He serves as a Director for JAGSONPAL Pharmaceuticals Ltd. He studied M.Sc. in Pharmacy.

CEO Compensation
  • Insufficient data for Rajpal to compare compensation growth.
  • Rajpal's remuneration is lower than average for companies of similar size in India.
Management Team Tenure

Average tenure of the Jagsonpal Pharmaceuticals management team in years:

7.8
Average Tenure
  • The average tenure for the Jagsonpal Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Rajpal Kochhar

TITLE
Chairman & MD
AGE
64
TENURE
11.3 yrs

Sanjiv Dudeja

TITLE
Chief Financial Officer

Raj Kapoor

TITLE
Company Secretary & Compliance Officer
TENURE
6.3 yrs

Prithipal Kochhar

TITLE
Vice President of International Business and International Marketing
COMPENSATION
₹2M
AGE
40
TENURE
7.8 yrs
Board of Directors Tenure

Average tenure and age of the Jagsonpal Pharmaceuticals board of directors in years:

6.3
Average Tenure
64
Average Age
  • The tenure for the Jagsonpal Pharmaceuticals board of directors is about average.
Board of Directors

Rajpal Kochhar

TITLE
Chairman & MD
AGE
64

Bharat Sinh

TITLE
Independent Director
COMPENSATION
₹48K
AGE
63
TENURE
6.3 yrs

Jasbir Kochhar

TITLE
Woman Director
TENURE
4.3 yrs

Ishpal Ghai

TITLE
Independent Director
COMPENSATION
₹48K
AGE
71
TENURE
6.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Jagsonpal Pharmaceuticals individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (₹) Value (₹)
28. Jun 19 Buy Rajpal Kochhar Individual 26. Jun 19 27. Jun 19 8,635 ₹25.60 ₹219,863
24. Jun 19 Buy Rajpal Kochhar Individual 21. Jun 19 21. Jun 19 1,573 ₹25.60 ₹40,261
26. Jun 19 Buy Rajpal Kochhar Individual 25. Jun 19 25. Jun 19 984 ₹25.55 ₹25,141
03. Apr 19 Buy Rajpal Kochhar Individual 01. Apr 19 02. Apr 19 8,414 ₹26.61 ₹223,066
31. Jan 19 Buy Rajpal Kochhar Individual 29. Jan 19 30. Jan 19 13,695 ₹30.38 ₹414,409
25. Jan 19 Buy Rajpal Kochhar Individual 24. Jan 19 24. Jan 19 1,946 ₹31.38 ₹61,063
23. Jan 19 Buy Rajpal Kochhar Individual 22. Jan 19 22. Jan 19 12,499 ₹31.05 ₹387,945
24. Jan 19 Buy Rajpal Kochhar Individual 23. Jan 19 23. Jan 19 3,170 ₹31.33 ₹99,305
09. Jan 19 Buy Rajpal Kochhar Individual 07. Jan 19 07. Jan 19 1 ₹31.00 ₹31
05. Jan 19 Buy Rajpal Kochhar Individual 04. Jan 19 04. Jan 19 1,226 ₹31.13 ₹38,164
04. Jan 19 Buy Rajpal Kochhar Individual 03. Jan 19 03. Jan 19 2,579 ₹31.13 ₹80,279
03. Jan 19 Buy Rajpal Kochhar Individual 02. Jan 19 02. Jan 19 1,108 ₹31.13 ₹34,489
27. Dec 18 Buy Rajpal Kochhar Individual 26. Dec 18 26. Dec 18 7,899 ₹30.48 ₹240,138
25. Dec 18 Buy Rajpal Kochhar Individual 24. Dec 18 24. Dec 18 12,257 ₹30.60 ₹374,215
22. Dec 18 Buy Rajpal Kochhar Individual 21. Dec 18 21. Dec 18 11,680 ₹30.59 ₹357,189
21. Dec 18 Buy Rajpal Kochhar Individual 19. Dec 18 19. Dec 18 7,751 ₹30.62 ₹236,779
08. Dec 18 Buy Rajpal Kochhar Individual 06. Dec 18 07. Dec 18 10,089 ₹27.85 ₹280,921
06. Dec 18 Buy Rajpal Kochhar Individual 05. Dec 18 05. Dec 18 48 ₹27.36 ₹1,313
03. Nov 18 Buy Rajpal Kochhar Individual 02. Nov 18 02. Nov 18 535 ₹28.15 ₹15,041
02. Nov 18 Buy Rajpal Kochhar Individual 31. Oct 18 31. Oct 18 9,264 ₹28.11 ₹260,427
30. Oct 18 Buy Rajpal Kochhar Individual 29. Oct 18 29. Oct 18 1 ₹28.05 ₹28
27. Oct 18 Buy Rajpal Kochhar Individual 26. Oct 18 26. Oct 18 8,812 ₹28.08 ₹247,420
26. Oct 18 Buy Rajpal Kochhar Individual 25. Oct 18 25. Oct 18 3,653 ₹28.10 ₹102,467
25. Oct 18 Buy Rajpal Kochhar Individual 24. Oct 18 24. Oct 18 4,556 ₹28.07 ₹127,823
24. Oct 18 Buy Rajpal Kochhar Individual 23. Oct 18 23. Oct 18 13,137 ₹28.06 ₹368,497
23. Oct 18 Buy Rajpal Kochhar Individual 22. Oct 18 22. Oct 18 4,508 ₹28.10 ₹126,074
20. Oct 18 Buy Rajpal Kochhar Individual 19. Oct 18 19. Oct 18 7,254 ₹27.95 ₹202,604
18. Oct 18 Buy Rajpal Kochhar Individual 17. Oct 18 17. Oct 18 6,308 ₹28.07 ₹177,013
17. Oct 18 Buy Rajpal Kochhar Individual 16. Oct 18 16. Oct 18 5,708 ₹28.08 ₹159,725
16. Oct 18 Buy Rajpal Kochhar Individual 15. Oct 18 15. Oct 18 1,840 ₹27.10 ₹49,744
12. Oct 18 Buy Rajpal Kochhar Individual 11. Oct 18 11. Oct 18 3,247 ₹26.11 ₹84,726
11. Oct 18 Buy Rajpal Kochhar Individual 10. Oct 18 10. Oct 18 3 ₹26.00 ₹78
10. Oct 18 Buy Rajpal Kochhar Individual 09. Oct 18 09. Oct 18 17,449 ₹25.68 ₹447,322
09. Oct 18 Buy Rajpal Kochhar Individual 08. Oct 18 08. Oct 18 8,685 ₹26.03 ₹225,729
04. Oct 18 Buy Rajpal Kochhar Individual 03. Oct 18 03. Oct 18 5,628 ₹25.85 ₹145,334
18. Sep 18 Buy Rajpal Kochhar Individual 17. Sep 18 17. Sep 18 2,520 ₹30.27 ₹76,232
05. Sep 18 Sell Rajpal Kochhar Individual 29. Aug 18 29. Aug 18 -1 ₹36.00 ₹-36
05. Sep 18 Buy Rajpal Kochhar Individual 03. Sep 18 03. Sep 18 6,620 ₹33.06 ₹218,378
06. Sep 18 Buy Rajpal Kochhar Individual 05. Sep 18 05. Sep 18 11,719 ₹32.78 ₹383,810
01. Sep 18 Buy Rajpal Kochhar Individual 31. Aug 18 01. Sep 18 254 ₹29.35 ₹7,452
31. Aug 18 Buy Rajpal Kochhar Individual 30. Aug 18 30. Aug 18 553 ₹29.37 ₹16,242
29. Aug 18 Buy Rajpal Kochhar Individual 28. Aug 18 28. Aug 18 4,937 ₹29.41 ₹144,908
28. Aug 18 Buy Rajpal Kochhar Individual 27. Aug 18 27. Aug 18 5,050 ₹29.16 ₹147,250
17. Aug 18 Buy Rajpal Kochhar Individual 16. Aug 18 16. Aug 18 179 ₹27.11 ₹4,853
31. Jul 18 Buy Rajpal Kochhar Individual 30. Jul 18 30. Jul 18 3,604 ₹26.11 ₹94,051
26. Jul 18 Buy Rajpal Kochhar Individual 25. Jul 18 25. Jul 18 11,636 ₹26.02 ₹302,674
27. Jul 18 Buy Rajpal Kochhar Individual 26. Jul 18 26. Jul 18 2,170 ₹26.15 ₹56,668
25. Jul 18 Buy Rajpal Kochhar Individual 24. Jul 18 24. Jul 18 14,814 ₹24.93 ₹367,967
X
Management checks
We assess Jagsonpal Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Jagsonpal Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Has A Pretty Healthy Balance Sheet

NSEI:JAGSNPHARM Historical Debt, July 11th 2019 How Strong Is Jagsonpal Pharmaceuticals's Balance Sheet? … While Jagsonpal Pharmaceuticals has net cash on its balance sheet, it's still worth taking a look at its ability to convert earnings before interest and tax (EBIT) to free cash flow, to help us understand how quickly it is building (or eroding) that cash balance. … Summing up While it is always sensible to investigate a company's debt, in this case Jagsonpal Pharmaceuticals has ₹347m in net cash and a decent-looking balance sheet.

Simply Wall St -

Should Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) Be Part Of Your Dividend Portfolio?

While Jagsonpal Pharmaceuticals's 0.4% dividend yield is not the highest, we think its lengthy payment history is quite interesting. … With a strong net cash balance, Jagsonpal Pharmaceuticals investors may not have much to worry about in the near term from a dividend perspective. … For the purpose of this article, we only scrutinise the last decade of Jagsonpal Pharmaceuticals's dividend payments.

Simply Wall St -

Can We See Significant Insider Ownership On The Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) Share Register?

Every investor in Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) should be aware of the most powerful shareholder groups. … With a market capitalization of ₹677m, Jagsonpal Pharmaceuticals is a small cap stock, so it might not be well known by many institutional investors. … Check out our latest analysis for Jagsonpal Pharmaceuticals

Simply Wall St -

Have Insiders Been Buying Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) Shares?

We don't think shareholders should simply follow insider transactions. … The Last 12 Months Of Insider Transactions At Jagsonpal Pharmaceuticals … While there weren't any large insider transactions in the last twelve months, it's still worth looking at the trading

Simply Wall St -

Who Are The Major Shareholders Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)?

A look at the shareholders of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) can tell us which group is most powerful. … Taking a look at the our data on the ownership groups (below), it's seems that. … View our latest analysis for Jagsonpal Pharmaceuticals

Simply Wall St -

Is Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) PE Ratio A Signal To Sell For Investors?

The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market. … and want to better understand how you can grow your money by investing in Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM). … Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) is trading with a trailing P/E of 25x, which is higher than the industry average of 23.5x.

Simply Wall St -

What Investors Should Know About Jagsonpal Pharmaceuticals Limited's (NSEI:JAGSNPHARM) Financial Strength

How does JAGSNPHARM’s operating cash flow stack up against its debt? … With this debt payback, the current cash and short-term investment levels stands at ₹200.6M for investing into the business. … Although JAGSNPHARM’s debt level is relatively low, its cash flow levels still could not copiously cover its borrowings.

Simply Wall St -

Company Info

Description

Jagsonpal Pharmaceuticals Limited develops and manufactures active pharmaceutical ingredients (APIs) and formulations. Its APIs include allylestrenol, dextropropoxyphene HCL, dextropropoxyphene napsylate, disulfiram, thiopental sodium, thiopental acid, tolnaftate, and sildenafil citrate, as well as metformin HCL, BP, USP, and EP. The company also offers formulations for various therapeutic categories, such as anabolic steroids, analgesics, anesthetics, anti-allergic, anti-asthamatics, anti-cholinergic agents, anti-convulsants, anti-diabetics, anti-diarrhoeals, anti-emetics, anti-epileptics, anti-fungal agents, anti-gout agents, anti-inflammatory agents, anti-malarials, anti-nauseants, anti-protozoals, anti-pyretic, anti-rheumatic drugs, anti-spasmodic agents, and anti-septic agents. In addition, it provides anti-tubercular drugs, anti-ulcerants, anxiolytics, cardiovascular drugs, corticosteroids, cough syrups, diuretics, drugs for alcohol dependence, GI anti-infectives, haematinics, imaging agents, laxatives, male/female hormones, multivitamins, nutraceuticals, ophthalmic lubricants, oral rehydrating salts, sedative-hypnotics, softgels, systemic anti-infectives, throat pain sprays, tonics, and uterine stimulants. The company sells its products under the Lycored, Maintane, Metadec, Metabol, Doxypal DR, Parvon, and Indocap SR brand names through agents worldwide. Jagsonpal Pharmaceuticals Limited was founded in 1964 and is based in New Delhi, India. The company is a subsidiary of Aresko Progressive Private Limited.

Details
Name: Jagsonpal Pharmaceuticals Limited
JAGSNPHARM
Exchange: NSEI
Founded: 1964
₹622,202,500
26,198,000
Website: http://www.jagsonpal.com
Address: Jagsonpal Pharmaceuticals Limited
T-210J, Shahpur Jat,
New Delhi,
Delhi, 110049,
India
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NSEI JAGSNPHARM Equity Shares National Stock Exchange of India IN INR 01. Mar 2000
BSE 507789 Equity Shares Mumbai Stock Exchange IN INR 01. Mar 2000
Number of employees
Current staff
Staff numbers
0
Jagsonpal Pharmaceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/18 12:53
End of day share price update: 2019/07/18 00:00
Last earnings filing: 2019/05/28
Last earnings reported: 2019/03/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.